With an expiration date still more than a year away, here's what the latest details reveal.
GlobalData on MSN
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.
The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...
It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, ...
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
Scientists are changing their view of how drugs like Adderall and Ritalin help children with ADHD stay on task. NPR's Jon Hamilton reports on a new study that found the drugs act on brain networks ...
From 2022 to 2024, stimulant prescriptions issued in Connecticut increased by 13.2 percent, according to data from the state.
Scientists are updating their view of how drugs like Adderall and Ritalin help children with attention deficit hyperactivity disorder stay on task. The latest evidence is a study of thousands of brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results